Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Calidi Biotherapeutics Inc (AMEX: CLDI) closed at $0.35 down -1.23% from its previous closing price of $0.35. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 1.99 million shares were traded.
Ratios:
For a deeper understanding of Calidi Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 22, 2023, initiated with a Buy rating and assigned the stock a target price of $11.
On October 09, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’24 when Camaisa Allan sold 10,000 shares for $1.62 per share. The transaction valued at 16,200 led to the insider holds 66,712 shares of the business.
Stock Price History:
Over the past 52 weeks, CLDI has reached a high of $3.89, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is -28.07%, while the 200-Day Moving Average is calculated to be -68.09%.
Shares Statistics:
A total of 31.79M shares are outstanding, with a floating share count of 29.70M. Insiders hold about 6.57% of the company’s shares, while institutions hold 17.13% stake in the company.
Earnings Estimates
The current market rating for Calidi Biotherapeutics Inc (CLDI) reflects the collective analysis of 1 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.45 and -$0.45 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.32, with 1.0 analysts recommending between -$0.32 and -$0.32.
